MarketCap
Facebook
X
TelegramAnnual report 2023
added 12-27-2025
Profound Medical Corp. Total Assets 2011-2026 | PROF
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Profound Medical Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 43.9 M | 64.4 M | 86.8 M | 105 M | - | - | 27.9 M | 17.6 M | 15.3 M | 1.47 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 1.47 M | 45.2 M |
Quarterly Total Assets Profound Medical Corp.
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 86.8 M | - | - | - | 105 M | - | - | - | 30.1 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 105 M | 30.1 M | 73.8 M |
Total Assets of other stocks in the Medical devices industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
54 M | - | -26.83 % | $ 2.62 M |  USA |
 |
LivaNova PLC
LIVN
|
2.61 B | $ 69.84 | 1.14 % | $ 3.79 B |  Britain |
 |
Allied Healthcare Products
AHPI
|
19.7 M | - | 3.58 % | $ 2.21 M | USA |
 |
GenMark Diagnostics, Inc.
GNMK
|
224 M | - | - | $ 1.77 B | USA |
 |
Cognyte Software Ltd.
CGNT
|
498 M | $ 6.61 | 3.44 % | $ 475 M |  Israel |
 |
Apollo Endosurgery
APEN
|
110 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
791 M | $ 13.85 | -0.57 % | $ 2.08 B | USA |
 |
Avinger
AVGR
|
13.8 M | - | -20.74 % | $ 369 K | USA |
 |
Obalon Therapeutics, Inc.
OBLN
|
10.6 M | - | -5.86 % | $ 30.6 M | USA |
 |
AxoGen
AXGN
|
222 M | $ 31.25 | -3.85 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
659 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
43.4 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
79.2 M | $ 3.46 | -2.26 % | $ 120 M | USA |
 |
Conformis
CFMS
|
94 M | - | - | $ 16.4 M | USA |
 |
Bio-Rad Laboratories
BIO
|
9.36 B | $ 269.55 | 0.25 % | $ 7.61 B | USA |
 |
BIOLASE
BIOL
|
35.1 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
86.1 M | $ 4.63 | 3.58 % | $ 173 M |  France |
 |
Bruker Corporation
BRKR
|
5.81 B | $ 39.92 | 0.38 % | $ 5.95 K | USA |
 |
BioSig Technologies
BSGM
|
842 K | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
43.7 B | $ 74.02 | -1.5 % | $ 110 B | USA |
 |
CryoLife, Inc.
CRY
|
789 M | - | -4.14 % | $ 702 M | USA |
 |
ClearPoint Neuro
CLPT
|
39.2 M | $ 15.18 | 4.3 % | $ 410 M | USA |
 |
CONMED Corporation
CNMD
|
2.33 B | $ 46.01 | -0.07 % | $ 1.43 B | USA |
 |
Soliton, Inc.
SOLY
|
33.8 M | - | -1.42 % | $ 435 M | USA |
 |
Cardiovascular Systems
CSII
|
323 M | - | 0.15 % | $ 844 M | USA |
 |
Hancock Jaffe Laboratories, Inc.
HJLI
|
10.5 K | - | -1.98 % | $ 98.3 M | USA |
 |
Itamar Medical Ltd.
ITMR
|
64.1 M | - | 0.03 % | $ 1.58 B | Israel |
 |
Misonix, Inc.
MSON
|
204 M | - | - | $ 462 M | USA |
 |
Neovasc
NVCN
|
66.2 M | - | - | $ 111 M |  Canada |
 |
InMode Ltd.
INMD
|
766 M | $ 13.96 | -0.14 % | $ 902 M | Israel |
 |
Cutera
CUTR
|
346 M | - | -10.19 % | $ 1.99 M | USA |
 |
Delcath Systems
DCTH
|
76.6 M | $ 10.16 | 2.11 % | $ 290 M | USA |
 |
Intersect ENT, Inc.
XENT
|
227 M | - | - | $ 955 M | USA |
 |
Dynatronics Corporation
DYNT
|
15.4 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
132 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
53.8 M | $ 23.53 | 1.64 % | $ 199 M | USA |
 |
Second Sight Medical Products
EYES
|
41.6 M | - | -0.97 % | $ 54.4 M | USA |
 |
Establishment Labs Holdings
ESTA
|
347 M | $ 77.39 | -2.87 % | $ 2.18 B |  Costa-rica |
 |
Nano-X Imaging Ltd.
NNOX
|
210 M | $ 2.46 | 1.23 % | $ 144 M | Israel |
 |
GBS
GBS
|
8.25 M | - | -0.57 % | $ 7.12 M | USA |
 |
FONAR Corporation
FONR
|
199 M | $ 18.54 | -0.16 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
5.3 B | $ 95.57 | 3.99 % | $ 12.9 B | USA |
 |
Helius Medical Technologies
HSDT
|
7.69 M | $ 2.18 | 17.84 % | $ 1.33 M | USA |
 |
IRadimed Corporation
IRMD
|
98.3 M | $ 100.38 | 1.3 % | $ 1.27 B | USA |
 |
Invacare Corporation
IVC
|
771 M | - | - | $ 24.7 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
4.04 B | $ 11.54 | 0.09 % | $ 889 M | USA |
 |
Inogen
INGN
|
296 M | $ 6.07 | 3.94 % | $ 144 M | USA |